Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Drug metabolism reviews (Softcover ed.)

• Publication date

  2010-01-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/03602530903208652PMID 19821643PMCID PMC3072888
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

  2010cited by this paper
• Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.

  2009influential reference
• Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention

  2009cited by this paper
• Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines

  2008influential reference
• Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response

  2008cited by this paper
• Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.

  2008cited by this paper
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

  2008cited by this paper
• Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

  2007cited by this paper
• Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases

  2007influential reference
• The UDP-Glucuronosyltransferase 2B17 Gene Deletion Polymorphism: Sex-Specific Association with Urinary 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronidation Phenotype and Risk for Lung Cancer

  2007influential reference
• Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

  2007cited by this paper
• Elimination of Antiestrogenic Effects of Active Tamoxifen Metabolites by Glucuronidation

  2007cited by this paper
• Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

  2007cited by this paper
• Common deletion polymorphisms in the human genome

  2006influential reference
• Analysis of fracture risk factors from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial: 5-year data.

  2006cited by this paper
• Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

  2006influential reference
• Impact of chemotherapy regimens prior to endocrine therapy

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006influential reference
• Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.

  2006cited by this paper
• Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

  2006cited by this paper
• Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

  2006cited by this paper
• Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.

  2006cited by this paper
• The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

  2006cited by this paper
• Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.

  2006cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

  2005cited by this paper
• Interactions Between Antiretrovirals and Antineoplastic Drug Therapy

  2005cited by this paper
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

  2005cited by this paper
• The Effect of Exemestane on the Lipidemic Profile of Postmenopausal Early Breast Cancer Patients: Preliminary Results of the TEAM Greek Sub-study

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.

  2005cited by this paper
• INTERACTIONS OF THE STEREOISOMERS OF α-HYDROXYTAMOXIFEN WITH HUMAN HYDROXYSTEROID SULFOTRANSFERASE SULT2A1 AND RAT HYDROXYSTEROID SULFOTRANSFERASE STA

  2004cited by this paper
• Correlation between UDP-Glucuronosyltransferase Genotypes and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Glucuronidation Phenotype in Human Liver Microsomes

  2004influential reference
• Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

  2004influential reference
• Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15.

  2004cited by this paper
• Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4.

  2004influential reference
• Gene expression profiles of 4‐hydroxy‐N‐desmethyl‐tamoxifen (endoxifen)‐ and 4‐hydroxy‐tamoxifen (4OHTAM)‐treated human breast cancer cells determined by CDNA microarray analysis

  2004cited by this paper
• Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

  2004influential reference
• Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4.

  2004influential reference
• Oxidative metabolism of tamoxifen to Z‐4‐hydroxy‐tamoxifen by cytochrome P450 isoforms: An appraisal of in vitro studies

  2003cited by this paper
• CYP2D6-mediated catalysis of tamoxifen aromatic hydroxylation with an NIH shift: similar hydroxylation mechanism in chicken, rat and human liver microsomes

  2003cited by this paper
• A Human Minor Histocompatibility Antigen Resulting from Differential Expression due to a Gene Deletion

  2003influential reference
• Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

  2003influential reference
• Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes.

  2003cited by this paper
• New approaches to the endocrine prevention and treatment of breast cancer

  2003cited by this paper
• Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk

  2003cited by this paper
• Overview of the main outcomes in breast-cancer prevention trials.

  2003cited by this paper
• Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases.

  2002influential reference
• The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.

  2002influential reference
• Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3.

  2002cited by this paper
• Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.

  2002cited by this paper
• 4‐Hydroxytamoxifen sulfation metabolism

  2002cited by this paper
• Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues.

  2002influential reference
• Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.

  2002cited by this paper
• Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial

  2001cited by this paper
• Risk and Prognosis of Endometrial Cancer After Tamoxifen for Breast Cancer

  2001cited by this paper
• Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.

  2001cited by this paper
• Estrogen production and action.

  2001cited by this paper
• Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members.

  2001influential reference
• Comparative N-glucuronidation kinetics of ketotifen and amitriptyline by expressed human UDP-glucuronosyltransferases and liver microsomes.

  2000cited by this paper
• O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9.

  2000influential reference
• Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.

  2000cited by this paper
• Exemestane in advanced breast cancer

  2000cited by this paper
• Exemestane for advanced breast cancer.

  2000cited by this paper
• Risk and prognosis of endometrial cancer after tamoxifen for breast cancer

  2000cited by this paper
• Tamoxifen therapy for breast cancer and endometrial cancer risk.

  1999cited by this paper
• Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus.

  1999influential reference
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1998cited by this paper
• Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins.

  1998cited by this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268).

  1998cited by this paper
• Aromatase expression of human osteoblast-like cells.

  1998cited by this paper
• Tamoxifen and risk of idiopathic venous thromboembolism.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.

  1997cited by this paper
• Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.

  1997cited by this paper
• Enzymology of human cytosolic sulfotransferases

  1997cited by this paper
• Absolute bioavailability of letrozole in healthy postmenopausal women

  1997cited by this paper
• Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein.

  1996cited by this paper
• Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.

  1995cited by this paper
• Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Risk of endometrial cancer after tamoxifen treatment of breast cancer.

  1994cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age.

  1994cited by this paper
• Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.

  1993influential reference
• Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.

  1993cited by this paper
• Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione).

  1993cited by this paper
• Clinical Pharmacokinetics of Endocrine Agents Used in Advanced Breast Cancer

  1992cited by this paper
• Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues.

  1991influential reference
• Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.

  1991cited by this paper
• Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes.

  1991influential reference
• Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.

  1989influential reference
• Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile.

  1988cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1988cited by this paper
• Aromatase activity in human skin fibroblasts grown in cell culture.

  1987cited by this paper
• Aromatization by skeletal muscle.

  1986cited by this paper

• Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients

  2025cites this paper
• Quantification of the aromatase inhibitor letrozole and its carbinol metabolite in mouse plasma by UHPLC-MS/MS.

  2024cites this paper
• Study of viscosity and thermodynamics a dual mixture of surfactants with tamoxifen at different temperatures

  2022cites this paper
• The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation

  2022cites this paper
• Anastrozole and related glucuronic acid conjugate are electrophilic species

  2022cites this paper
• Anti-oxidant, anti-diabetic and anti-lipidemic activities of root bark extracts from Rhus tripartitum and cytotoxicity evaluation of isolated compounds

  2022cites this paper
• Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites

  2021cites this paper
• Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer

  2021cites this paper
• Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy

  2021cites this paper
• Berberine induces apoptosis and arrests the cell cycle in multiple cancer cell lines

  2021cites this paper
• Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients

  2020cites this paper
• Practice of Epidemiology Bayesian Pathway Analysis for Complex Interactions

  2020cites this paper
• Role of Phytochemicals in Regulation of Cancer Cells: A Comprehensive Literature Review

  2020cites this paper
• Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial

  2020cites this paper
• Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients’ Population

  2020cites this paper
• Impact of CYP3A4 and CYP3A5 single nucleotide polymorphisms on anastrozole-associated adverse events among Malaysian breast cancer patients

  2019cites this paper
• Anastrozole as aromatase inhibitor – new approaches to breast cancer treatment in postmenopausal women

  2019cites this paper
• Predictive Value of Microdose Pharmacokinetics

  2019cites this paper
• Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer

  2019cites this paper
• Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Male Volunteers: A Randomized, Single‐Dose, Two‐Period, Two‐Sequence Crossover Study

  2019cites this paper
• Pharmacogenetics of drugs in breast cancer and new approaches for improvement of their bioavailability

  2019cites this paper
• Association between ESR1, ESR2, HER2, UGT1A4, and UGT2B7 polymorphisms and breast Cancer in Jordan: a case-control study

  2019cites this paper
• Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis

  2019cites this paper
• Tamoxifen: From Anti-cancer to Antifungal Drug

  2019cites this paper
• Anastrozol jako inhibitor aromatazy – nowe podejścia w terapii raka piersi u kobiet w wieku pomenopauzalnym

  2019cites this paper
• Impact of CYP 3 A 4 and CYP 3 A 5 single nucleotide polymorphisms on anastrozole-associated adverse events among Malaysian breast cancer patients

  2019cites this paper
• POVEZANOST SKLEROSTINA I DICKKOPFA 1 TE FUNKCIONALNIH GENSKIH POLIMORFIZAMA INHIBITORA AROMATAZE S INDIVIDUALNIM RAZLIKAMA U UČESTALOSTI I TEŽINI NEŽELJENIH POPRATNIH POJAVA LIJEČENJA

  2018influential citation
• Methods for detection of the misuse of “anti-oestrogens and aromatase inhibitors” in sport

  2017cites this paper
• Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers

  2017cites this paper
• IN VITRO ANTICANCER ACTIVITY OF ENDOPHYTIC FUNGAL EXTRACTS FROM CLADOSPORIUM FAMILY ISOLATED FROM CYATHOCLINE PURPUREA (D. DON.) O. KTZE

  2017cites this paper
• Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters

  2016cites this paper
• Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.

  2016cites this paper
• A Review of Chromatographic Methods Used in the Determination of Anastrozole Levels

  2016cites this paper
• The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors

  2016influential citation
• Prediction of Response to Aromatase Inhibitors in Breast Cancer

  2015cites this paper
• Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism

  2015cites this paper
• MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors

  2015cites this paper
• Resistance to Aromatase Inhibitors in Breast Cancer

  2015cites this paper
• Tamoxifen metabolites can target both aromatase and estrogen receptors

  2015cites this paper
• The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients

  2014cites this paper
• Dual Roles for Splice Variants of the Glucuronidation Pathway as Regulators of Cellular Metabolism

  2014cites this paper
• Regulation of UDP-Glucuronosyltransferase 1A1 Expression and Activity by MicroRNA 491-3p

  2014cites this paper
• A Potential Role for Human UDP-Glucuronosyltransferase 1A4 Promoter Single Nucleotide Polymorphisms in the Pharmacogenomics of Tamoxifen and Its Derivatives

  2014cites this paper
• DMD058016 1392..1400

  2014cites this paper
• Étude fonctionnelle des variants d'épissage des UGT1A humains

  2014cites this paper
• Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

  2014cites this paper
• Dual roles for splice variants of the glucuronidation pathway as regulators of cellular metabolism .

  2013cites this paper
• Potential Role of UGT1A4 Promoter SNPs in Anastrozole Pharmacogenomics

  2013influential citation
• Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer

  2013cites this paper
• The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7

  2013cites this paper
• Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells.

  2012cites this paper
• SNP web resources and their potential applications in personalized medicine.

  2012cites this paper
• Role of the Uridine Diphosphate Glucuronosyltransferase 2a Family in Tobacco Carcinogen Metabolism

  2012cites this paper
• Pharmacogenomics of third-generation aromatase inhibitors

  2012influential citation
• UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population

  2012cites this paper
• Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS

  2012cites this paper
• Evaluation of cytotoxic effects of several novel tetralin derivatives against Hela, MDA-MB-468, and MCF-7 cancer cells

  2012cites this paper
• Role of Human UDP-Glucuronosyltransferases in the Biotransformation of the Triazoloacridinone and Imidazoacridinone Antitumor Agents C-1305 and C-1311: Highly Selective Substrates for UGT1A10

  2012cites this paper
• Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches

  2012cites this paper
• Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatography-tandem mass spectrometry.

  2012cites this paper
• Alternative Androgen Metabolism in Resistance to Aromatase Inhibitors.

  2011cites this paper
• UDP-glucuronosyltransferase 2B7 glucuronidation of the active tamoxifen metabolites

  2011cites this paper
• Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants

  2011cites this paper
• Genomics and pharmacogenomics of breast cancer: current knowledge and trends.

  2011influential citation
• Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes

  2011cites this paper
• Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics

  2010cites this paper
• Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

  2010cites this paper
• Pharmacogenetics of Aromatase Inhibitors: Present Understanding and Looking to the Future

  2010cites this paper
• Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer.

  2010cites this paper
• Aromatase inhibitors: prediction of response and nature of resistance

  2010cites this paper
• In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.

  2010cites this paper
• Pharmacogenomics of tamoxifen therapy.

  2009cites this paper